Kilitch Drugs (India) kilitch drugs shareholders approved all resolutions at its 34th Annual General Meeting on August 27, 2026. The scrutinizer’s report confirmed that every agenda item secured the requisite majority to pass.

The meeting, chaired by Managing Director Mukund Mehta, was conducted via video conferencing from 9:00 am to 9:51 am. Shareholders voted on four key items: adoption of FY26 financials, re-appointment of Mukund Mehta, approval of performance-linked incentives for executive directors, and ratification of the cost auditor’s remuneration.

Voting Results

All resolutions received 95% support in favor, with 5% votes cast against. No invalid votes were recorded. The voting breakdown by shareholder category reveals distinct patterns in engagement and support.

Promoters held 22,296,346 shares as on August 20, 2026, and voted unanimously in favor of all resolutions. Institutional investors also showed full support, though their participation rate was low at just 3.37% of their holdings.

What the Numbers Show

The divergence between promoter and public non-institutional voting is notable. While promoters provided blanket approval, public non-institutions split their votes almost evenly, with 52.48% supporting and 47.52% opposing the resolutions. This opposition accounted for all 1,190,002 negative votes recorded across the meeting.

Participation rates varied significantly across categories. Promoters engaged fully (100% of shares), while public institutions participated minimally (3.37%). Public non-institutions showed moderate engagement at 19.95% of outstanding shares.

Governance Details

M/s. Deep Shukla & Associates served as the scrutinizer for the e-voting process. The company used M/s. MUFG Intime India Private Limited’s platform for remote e-voting, which ran from August 20 to August 27, 2026.

Statutory auditors C Sharat and Associates, secretarial auditor Deep Shukla & Associates, and cost auditor Arvind Kumar and Co. attended the meeting. The proceedings complied with the Companies Act, 2013, and SEBI Listing Obligations regulations.

Kilitch Drugs reported mixed financial results for the first quarter, posting revenue growth alongside a contraction in operating margins. While the company managed to expand its top line, cost pressures or lower operating leverage led to a decline in both absolute EBITDA and net profit compared to the previous year.

The pharma firm logged Q1 revenue of ₹449 million, an increase from ₹431 million recorded in the corresponding period last year. Despite this top-line expansion, the company’s earnings before interest, taxes, depreciation, and amortization (EBITDA) slipped to ₹29 million, down from ₹33 million in the prior year quarter.

Financial Performance

The divergence between revenue growth and profit decline highlights a squeeze on operational efficiency during the period. The EBITDA margin contracted to 6.53% from 7.56% in the previous year, indicating that costs rose faster than sales. Consequently, net profit also faced downward pressure, falling to ₹29 million from ₹30 million year-on-year.

What the Numbers Show

The data reveals a clear decoupling of top-line growth from bottom-line performance. While Kilitch Drugs successfully grew its revenue base by approximately 4%, this expansion did not translate into proportional operating gains. Instead, the 12% drop in EBITDA suggests increased input costs, pricing pressures, or higher operational expenses that eroded the margin by over 100 basis points. This pattern indicates that while market share or volume may have improved, the economic value generated per rupee of sales has diminished.